Literature DB >> 16776855

Phytoestrogens and cardiovascular disease.

Aedín Cassidy1, Lee Hooper.   

Abstract

The most extensively studied class of phytoestrogens, isoflavones, occur in soybeans and other legumes. Six systematic reviews have assessed the effects of soy isoflavones on lipid levels, and suggested that a diet supplemented with soy protein isolate (ISP) containing isoflavones reduces low-density lipoprotein (LDL) cholesterol by around 0.15 mmol/L, but without clear effects on triglycerides or high-density lipoprotein (HDL) cholesterol. However, no review has suggested that purified soy isoflavones or soy protein without isoflavones (where the isoflavones have been removed by an alcohol wash) have statistically significant effects. It remains unclear which are the active components of soy. They may include soy protein which has not been denatured by alcohol wash, interaction of isoflavones within the intact soy matrix, or other compounds removed in the alcohol-extracted fraction. The reduction in total cholesterol may be greater in men than in postmenopausal women. There is little evidence that the effectiveness of soy varies with baseline serum lipid levels, or the amount of isoflavone or soy protein consumed. However, changes in triglycerides may be related to baseline levels. While there is no evidence of beneficial effects of phytoestrogens on blood pressure, arterial compliance or oxidation of LDL cholesterol, there may be beneficial effects on endothelial function in postmenopausal women, and on homocysteine concentrations. There is little suggestion of adverse effects of soy or isoflavones at physiological doses, although those taking soy isoflavone supplements do appear to have higher levels of gastro intestinal and menstrual complaints. There have been no published trials on the effects of phytoestrogens on mortality or cardiovascular events, so studies currently rely on the above bio markers of risk. Most evidence relates to soy isoflavones, but there is some evidence for lignans. Further robust studies assessing the effects of whole soy foods on cardiovascular outcomes are needed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16776855     DOI: 10.1258/136218006777525776

Source DB:  PubMed          Journal:  J Br Menopause Soc        ISSN: 1362-1807


  11 in total

1.  Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk.

Authors:  Kenneth D R Setchell; Nadine M Brown; Xueheng Zhao; Stephanie L Lindley; James E Heubi; Eileen C King; Mark J Messina
Journal:  Am J Clin Nutr       Date:  2011-09-28       Impact factor: 7.045

2.  The effects of soy consumption before diagnosis on breast cancer survival: the Multiethnic Cohort Study.

Authors:  Shannon M Conroy; Gertraud Maskarinec; Song-Yi Park; Lynne R Wilkens; Brian E Henderson; Laurence N Kolonel
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

3.  Soy protein containing isoflavones favorably influences macrophage lipoprotein metabolism but not the development of atherosclerosis in CETP transgenic mice.

Authors:  Leiko Asakura; Patrícia M Cazita; Lila M Harada; Valéria S Nunes; Jairo A Berti; Alessandro G Salerno; Daniel F J Ketelhuth; Magnus Gidlund; Helena C F Oliveira; Eder C R Quintão
Journal:  Lipids       Date:  2006-07       Impact factor: 1.880

4.  Soy food intake and breast cancer survival.

Authors:  Xiao Ou Shu; Ying Zheng; Hui Cai; Kai Gu; Zhi Chen; Wei Zheng; Wei Lu
Journal:  JAMA       Date:  2009-12-09       Impact factor: 56.272

5.  Reduction of body weight, liver steatosis and expression of stearoyl-CoA desaturase 1 by the isoflavone daidzein in diet-induced obesity.

Authors:  A Crespillo; M Alonso; M Vida; F J Pavón; A Serrano; P Rivera; Y Romero-Zerbo; P Fernández-Llebrez; A Martínez; V Pérez-Valero; F J Bermúdez-Silva; J Suárez; F R de Fonseca
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

6.  Effect of soy isoflavones on breast cancer recurrence and death for patients receiving adjuvant endocrine therapy.

Authors:  Xinmei Kang; Qingyuan Zhang; Shuhuai Wang; Xu Huang; Shi Jin
Journal:  CMAJ       Date:  2010-10-18       Impact factor: 8.262

7.  Involvement of estrogen receptor-β in farrerol inhibition of rat thoracic aorta vascular smooth muscle cell proliferation.

Authors:  Qun-yi Li; Li Chen; Yan-hui Zhu; Meng Zhang; Yi-ping Wang; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2011-03-14       Impact factor: 6.150

8.  Genistein, a soy phytoestrogen, upregulates the expression of human endothelial nitric oxide synthase and lowers blood pressure in spontaneously hypertensive rats.

Authors:  Hongwei Si; Dongmin Liu
Journal:  J Nutr       Date:  2008-02       Impact factor: 4.798

9.  Isoflavone genistein protects human vascular endothelial cells against tumor necrosis factor-alpha-induced apoptosis through the p38beta mitogen-activated protein kinase.

Authors:  Hongwei Si; Dongmin Liu
Journal:  Apoptosis       Date:  2009-01       Impact factor: 4.677

10.  Effect of isoflavones on cardiovascular health: low but not out either.

Authors:  Biju C Mathew; Reji Susan Daniel
Journal:  J Clin Biochem Nutr       Date:  2008-09       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.